Abstract:
The critical role of gut microbiota in tumorigenesis, progression and treatment response has been widely confirmed. As an important tool for regulating microecological balance, probiotics have shown great potential in the field of adjuvant tumor therapy, but their clinical translation still faces significant controversies and challenges. This review first systematically sorts out the current application status of probiotics in tumor therapy, and focuses on elaborating the molecular mechanisms by which probiotics exert adjuvant anti-tumor effects through multiple pathways, including immune checkpoint pathway regulation, anti-proliferative effects mediated by metabolites (especially short-chain fatty acids), intestinal barrier strengthening, and immune remodeling of the tumor microenvironment. On this basis, the article objectively analyzes the clinical evidence of probiotics in enhancing the efficacy of chemotherapy and immune checkpoint inhibitors (ICIs) and reducing treatment-related toxicity, and particularly emphasizes the conflicting evidence and potential risks of probiotics in ICIs therapy. Finally, this review deeply discusses the core challenges faced by current clinical translation, such as strain specificity, safety and evidence heterogeneity, and looks forward to the development direction of next-generation personalized probiotic therapies based on multi-omics integration and genetic engineering modification, in order to provide a reference for the formulation of precise microbiome-based adjuvant treatment strategies.